EGFR and non-small cell lung carcinoma: However, the addition of cetuximab to afatinib did not improve the outcomes in previously untreated EGFR‐mutant NSCLC patients but led to greater toxicity, including a 72% incidence rate of grade ≥ 3 treatment‐related adverse events.53